Jul 11, 2025 | Comparative Effectiveness, Cost Savings, Drug advertising, Drug costs, Health care costs, High-value formulary, MedBen Rx, Pharmacy, Rx Costs, Spending
Pharmaceutical advertising hit a record high in 2024, with the top 10 drugs accounting for $3.3 billion in ad spending – up nearly 20% from the previous year. With more campaigns directly targeting consumers, MedBen Rx’s high-value formulary educates members about...
Jul 1, 2025 | Cost Savings, Drug costs, GLP-1s, MedBen Rx, Ozempic, Rebates, Rx Costs, Specialty Drugs, Wegovy, Weight loss drugs
The 2025 Milliman Medical Index confirms what many employers are seeing firsthand: prescription drug costs are rising faster than any other health care expense, with a 9.7% increase over the past year. To help employers reclaim their drug spend, MedBen Rx offers a...
Jun 3, 2025 | Alternative Reimbursement Strategies, Announcements, Client Report, Fair Market Pricing, Forensic claims review, MedBen Rx, MedBen WellLiving, Nutrigenomics, Pharmacogenomics
The 2025 MedBen Client Report is now available for download from MedBen.com! “As your TPA, MedBen takes an interest in your plan’s success that goes beyond claim processing,” Chairman & CEO Kurt Harden says in his Opening Note. “Our services and...
Feb 24, 2025 | Benefits preservation, Cost Savings, Drug costs, MedBen Rx, Rx Costs, Savings, Specialty Drugs
High-cost specialty drugs can make up more than 60% of a health plan’s pharmacy costs. MedBen Rx’s benefit preservation program is designed to make certain that members have continued access to medications while reducing specialty drug spend to the...
Feb 10, 2025 | Chronic conditions, Cost Savings, Drug costs, Flexible spending accounts (FSAs), Health care costs, MedBen Rx, Pharmacogenomics, Rx Costs, Savings
Now available through MedBen Rx, pharmacogenomic testing is transforming health care through safer and more effective personalized medicine. Determining how genes affect a person’s response to drugs not only improves patient outcomes, but it also helps control...
Jan 27, 2025 | Federal Trade Commission (FTC), MedBen Rx, News, Pharmacy Benefits Manager (PBM), Rx Costs, Specialty Drugs, Spread Pricing
Through specialty generic drug markups, three major pharmacy benefit managers (PBMs) earned a collective $7.3 billion above estimated acquisition costs over a five-year period, according to an interim report released by the Federal Trade Commission (FTC)....
